Conditions: Parkinson's Disease
Keywords: SPM 962 rotigotine Parkinson's disease concomitant use of L-dopa
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 130
Healthy volunteers: no

Brief summary:
The primary objective of this study is to investigate safety of SPM 962 in advanced PD patients in a multi-center, open-label, non-controlled study following once-daily multiple transdermal doses of SPM962 within a range of 4.5 to 36.0 mg (maximum treatment period: 54 weeks). Efficacy is also to be exploratory investigated.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: SPM 962
Intervention descriptions: intervention 1: SPM 962 transdermal patch once a daily up to 36.0 mg/day

Protocol document: